Edivoxetine | 1194508-25-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: Edivoxetine
• 英文别名: (R)-2-[5-fluoro-2-(methyloxy)phenyl]-1-(S)-morpholin-2-yl-1-(tetrahydro-2H-pyran-4-yl)ethanol；(1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(oxan-4-yl)ethanol
• CAS: 1194508-25-2
• 化学式: C₁₈H₂₆FNO₄
• 分子量: 339.407
• InChiKey: CPBHSHYQQLFAPW-ZWKOTPCHSA-N

物化性质

• 沸点：
  484.3±40.0 °C(Predicted)
• 密度：
  1.198±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  60
• 氢给体数：
  2
• 氢受体数：
  6

制备方法与用途

埃迪索雷托尼(LY2216684)是一种新型、强效且选择性的去甲肾上腺素再摄取抑制剂(NERI)，正在评估其作为辅助治疗重度抑郁症(MDD)的应用。

文献信息

• Morpholine derivatives as norepinephrine reuptake inhibitors
  申请人：Campbell Iain Gordan

  公开号：US20070083046A1

  公开（公告）日：2007-04-12

  Compounds of the general formula (1) are inhibitors of the reuptake of norepinephrine. As such, they may be useful for the treatment of disorders of the central and/or peripheral nervous system.

  通式为(1)的化合物是去甲肾上腺素再摄取抑制剂。因此，它们可能对中枢和/或外周神经系统的疾病治疗有用。
• Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
  申请人：Allen John Albert

  公开号：US20070015786A1

  公开（公告）日：2007-01-18

  Selective norepinephrine reuptake inhibitors are useful for the prevention or treatment of hot flashes, vasomotor symptoms, impulse control disorders or personality change due to a general medical condition.
• BIOMARKER-OPTIMIZED ADHD TREATMENT
  申请人：Lawrence Gilbert Donald

  公开号：US20080020387A1

  公开（公告）日：2008-01-24

  Methods of predicting patient responsiveness to treatment of attention-deficit/hyperactivity disorder (ADHD) with selective norepinephrine reuptake inhibitors; identifying individuals requiring a higher than normal dose of atomoxetine for treating ADHD; and predicting patient responsiveness to treatment of neuropsychiatric diseases or disorders responsive to treatment with selective norepinephrine reuptake inhibitors are provided. These methods are based on the identification of the variable number of tandem repeats (VNTR) polymorphism present in the 3′-untranslated region of the human dopamine transporter 1 (DAT 1) gene present in patient body fluid or tissue samples. Patients with a 10/10 VNTR genotype are considered poor responders to treatment with atomoxetine and other selective norepinephrine reuptake inhibitors for the indicated conditions.
• METHODS FOR TREATING FIBROMYALGIA
  申请人：KATZ Robert S.

  公开号：US20140121193A1

  公开（公告）日：2014-05-01

  The invention provides methods for treating or ameliorating cognitive dysfunction, fatigue, energy, concentration, mood, and pain associated with fibromyalgia using compositions containing methylphenidate or pharmaceutically equivalents thereof.
• US7423037B2
  申请人：——

  公开号：US7423037B2

  公开（公告）日：2008-09-09